506 related articles for article (PubMed ID: 30690043)
1. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
2. Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection.
Bigley TM; Reitsma JM; Terhune SS
J Virol; 2015 Oct; 89(20):10230-46. PubMed ID: 26223645
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
O'Brien MS; Markovich KC; Selleseth D; DeVita AV; Sethna P; Gentry BG
Antiviral Res; 2018 Oct; 158():255-263. PubMed ID: 30153445
[TBL] [Abstract][Full Text] [Related]
4. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
5. First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure.
Muller C; Tilloy V; Frobert E; Feghoul L; Garrigue I; Lepiller Q; Mirand A; Sidorov E; Hantz S; Alain S
Antiviral Res; 2022 Aug; 204():105361. PubMed ID: 35690130
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and clinical effects of letermovir (Prevymis
Ogawa M; Eto T
Nihon Yakurigaku Zasshi; 2019; 153(4):192-198. PubMed ID: 30971660
[TBL] [Abstract][Full Text] [Related]
7. Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir.
Piret J; Boivin G
Infect Dis Rep; 2024 Jan; 16(1):65-82. PubMed ID: 38247977
[TBL] [Abstract][Full Text] [Related]
8. In-depth genomic analyses identified novel letermovir resistance-associated substitutions in the cytomegalovirus UL56 and UL89 gene products.
Komatsu TE; Hodowanec AC; Colberg-Poley AM; Pikis A; Singer ME; O'Rear JJ; Donaldson EF
Antiviral Res; 2019 Sep; 169():104549. PubMed ID: 31279814
[TBL] [Abstract][Full Text] [Related]
9. The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease.
Hussein ITM; Brooks J; Bowlin TL
Antiviral Res; 2020 Apr; 176():104710. PubMed ID: 31940473
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of cellular STAT3 synergizes with the cytomegalovirus kinase inhibitor maribavir to disrupt infection.
Reitsma JM; Terhune SS
Antiviral Res; 2013 Nov; 100(2):321-7. PubMed ID: 24070820
[TBL] [Abstract][Full Text] [Related]
11. Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection.
Hakki M; Drummond C; Houser B; Marousek G; Chou S
Antiviral Res; 2011 Nov; 92(2):313-8. PubMed ID: 21906628
[TBL] [Abstract][Full Text] [Related]
12. Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections.
Gentry BG; Bogner E; Drach JC
Antiviral Res; 2019 Jan; 161():116-124. PubMed ID: 30472161
[TBL] [Abstract][Full Text] [Related]
13. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir.
Chou S
Antimicrob Agents Chemother; 2009 Jan; 53(1):81-5. PubMed ID: 18981262
[TBL] [Abstract][Full Text] [Related]
14. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient.
Schubert A; Ehlert K; Schuler-Luettmann S; Gentner E; Mertens T; Michel D
BMC Infect Dis; 2013 Jul; 13():330. PubMed ID: 23870704
[TBL] [Abstract][Full Text] [Related]
15. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.
Webel R; Hakki M; Prichard MN; Rawlinson WD; Marschall M; Chou S
J Virol; 2014 May; 88(9):4776-85. PubMed ID: 24522923
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes.
Piret J; Goyette N; Boivin G
Antiviral Res; 2022 Jun; 202():105328. PubMed ID: 35490740
[TBL] [Abstract][Full Text] [Related]
17. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27.
Komazin G; Ptak RG; Emmer BT; Townsend LB; Drach JC
J Virol; 2003 Nov; 77(21):11499-506. PubMed ID: 14557635
[TBL] [Abstract][Full Text] [Related]
18. Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection.
Faure Bardon V; Peytavin G; Lê MP; Guilleminot T; Elefant E; Stirnemann J; Leruez-Ville M; Ville Y
PLoS One; 2020; 15(4):e0232140. PubMed ID: 32353010
[TBL] [Abstract][Full Text] [Related]
19. New Locus of Drug Resistance in the Human Cytomegalovirus UL56 Gene Revealed by
Chou S; Satterwhite LE; Ercolani RJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914965
[TBL] [Abstract][Full Text] [Related]
20. Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus.
Drouot E; Piret J; Boivin G
Antivir Ther; 2016; 21(6):535-539. PubMed ID: 26844400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]